MiNA works in collaboration with leading academic institutions and international pharmaceutical organizations.

MiNA works in collaboration with leading academic institutions and international pharmaceutical organizations.

COLLABORATORS

In May 2017, Sosei Group Corporation made a strategic investment of £35m in MiNA. Sosei is an international biopharmaceutical company originating from Japan
In November 2017, Boehringer Ingelheim entered into a license and collaboration agreement with MiNA developing novel compounds to treat fibrotic liver diseases such as Non Alcoholic Steato-Hepatitis (NASH)
In November 2017, Innovate UK awarded MiNA and LGC Link a grant to develop liver targeted gene activation therapies for the treatment of liver diseases
In 2015 we entered in a multi-year collaborative research agreement with Imperial College London to discover and develop new saRNA medicines
Since 2014 we have been collaborating with the Bioinformatics core facility at NTNU Trondheim to discover new saRNA compounds
In 2017 we entered in a multi-year sponsored research agreement with Beth Israel Deaconess Medical School for preclinical research in lung cancer

We are seeking new R&D partners in academic research and
biopharmaceutical drug development in the following areas:

Opportunities to exploit our MTL-CEBPA drug candidate in additional
disease settings outside our current focus of HCC and Cirrhosis

New disease target opportunities to harness the potential of
our saRNA platform especially in haploinsifficiency driven diseases

New, scalable, delivery technologies that can extend the activity of
our saRNA compounds outside the liver by systemic or local administration

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close